Delivery Order SPE2DB22D1017-SPE2DB25FG9QD
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 4, 2025, by the Defense Logistics Agency (DLA) for Dupixent 200 mg/1.14 ml pen auto-injectors. The contract is valued at $1,935.84 with a firm fixed price structure and an ultimate completion date of August 5, 2025. This non-competitive delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $44,144.72 by the Defense Logistics Agency on August 4, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL). This competitively awarded, firm fixed-price contract carries no set-aside designation and is scheduled for completion by August 5, 2025. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $8,656.45 on August 29, 2025, for the supply of Dupixent 300 mg/2 ml pens (2 ml units) under a Defense Logistics Agency Medical Supply Chain contract. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 2, 2025, and performance to be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $26,119.30 for Dupixent 300 mg/2 ml pen (2 ml) under a firm fixed price contract with the Defense Logistics Agency's Medical Supply Chain. The award was made on July 30, 2025, with an ultimate completion date of July 31, 2025, and represents a non-set-aside, competitively awarded contract. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order by the Defense Logistics Agency (DLA) valued at $46,171.82 for the supply of Dupixent 300 mg/2 mL pen injectors with an ultimate completion date of September 18, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $6,077.05 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen (2 ml) on September 15, 2025, with completion scheduled for September 16, 2025. This firm fixed-price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $97,446.44 on August 29, 2025, for the supply of Dupixent 300 mg/2 ml pen (2 ml units). This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 2, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child contract under a larger vehicle, this delivery order falls under...
- The Defense Logistics Agency awarded a $10,317.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 15, 2025, with an ultimate completion date of August 18, 2025. This is a non-set-aside contract, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, serving military and veteran...
- The Defense Logistics Agency awarded a delivery order valued at $11,417.87 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen (2 ml) on August 29, 2025, with an ultimate completion date of September 2, 2025. This is a firm fixed price, non-set-aside contract with place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order valued at $17,370.55 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pens on September 18, 2025, with an ultimate completion date of September 19, 2025. This is a firm fixed-price, non-set-aside contract executed under an Indefinite Delivery Contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement through...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG9QDDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on August 12, 2025, for Dupixent 300 mg/2 ml pen (2 ml) with a ceiling value of $9,466.60. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 13, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (designated SPE2DX), a $999,999,999.00 comprehensive pharmaceutical support vehicle running through December 2026 that enables the company to supply pharmaceutical products and medical supplies to military healthcare programs globally. Dupixent is a specialty biologic medication used to treat inflammatory conditions including eczema, asthma, and chronic rhinosinusitis. This delivery order represents a typical transaction within AmerisourceBergen's extensive federal medical supply portfolio, which encompasses brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. The DLA Medical Supply Chain continues to leverage AmerisourceBergen's capabilities as a prime vendor to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through flexible contract vehicles designed to meet diverse pharmaceutical procurement requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.5k | 8/12/25 |